ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.750,92
0,00%
S&P 500
5.308,13
0,00%
US Dollar vs BRL
5,0979
-0,13%
Bitcoin
71.276,73
-0,24%
Brent Oil
82,355
-1,41%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Palisade Bio Inc (PALI)

  7. Palisade Bio Inc (PALI) Notícias

PALI

Palisade Bio (PALI)

Palisade Bio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PALI
DataHoraFonteTítuloCódigoCompanhia
21/05/202409:30GlobeNewswire Inc.Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse ModelsNASDAQ:PALIPalisade Bio Inc
20/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PALIPalisade Bio Inc
17/05/202417:51Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:PALIPalisade Bio Inc
16/05/202417:44Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
14/05/202409:05GlobeNewswire Inc.Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PALIPalisade Bio Inc
13/05/202417:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PALIPalisade Bio Inc
10/05/202417:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PALIPalisade Bio Inc
10/05/202417:37Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:PALIPalisade Bio Inc
08/05/202419:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PALIPalisade Bio Inc
08/05/202418:06Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PALIPalisade Bio Inc
07/05/202409:30GlobeNewswire Inc.Palisade Bio Appoints Margery Fischbein to its Board of DirectorsNASDAQ:PALIPalisade Bio Inc
07/05/202408:30GlobeNewswire Inc.Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
02/05/202409:30GlobeNewswire Inc.Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq RulesNASDAQ:PALIPalisade Bio Inc
01/05/202409:30GlobeNewswire Inc.Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)NASDAQ:PALIPalisade Bio Inc
23/04/202409:30GlobeNewswire Inc.Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine ApproachNASDAQ:PALIPalisade Bio Inc
16/04/202409:30GlobeNewswire Inc.Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ StoolNASDAQ:PALIPalisade Bio Inc
11/04/202410:15GlobeNewswire Inc.Palisade Bio to Participate in the Virtual Investor Lunch Break EventNASDAQ:PALIPalisade Bio Inc
10/04/202409:15GlobeNewswire Inc.Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™NASDAQ:PALIPalisade Bio Inc
03/04/202418:30GlobeNewswire Inc.Palisade Bio Announces 1-for-15 Reverse Stock SplitNASDAQ:PALIPalisade Bio Inc
27/03/202409:00GlobeNewswire Inc.Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate UpdateNASDAQ:PALIPalisade Bio Inc
15/02/202410:35GlobeNewswire Inc.Palisade Bio to Present at Digestive Disease Week (DDW) 2024NASDAQ:PALIPalisade Bio Inc
14/02/202416:54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PALIPalisade Bio Inc
13/02/202410:35GlobeNewswire Inc.Palisade Bio Provides Corporate Update and Reiterates GuidanceNASDAQ:PALIPalisade Bio Inc
08/02/202416:40GlobeNewswire Inc.Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board MembersNASDAQ:PALIPalisade Bio Inc
08/02/202410:05GlobeNewswire Inc.Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion LeadersNASDAQ:PALIPalisade Bio Inc
06/02/202419:01Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PALIPalisade Bio Inc
06/02/202419:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PALIPalisade Bio Inc
30/01/202411:25GlobeNewswire Inc.Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 MillionNASDAQ:PALIPalisade Bio Inc
29/01/202410:05GlobeNewswire Inc.Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis CongressNASDAQ:PALIPalisade Bio Inc
26/01/202418:45Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PALIPalisade Bio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PALI

Seu Histórico Recente

GATE
AZEROUSDT
Aleph Zero
NYSE
BN
Brookfield
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados